MMV253

Zydus Cadila

Legend
Product vision

  • Part of a single-exposure radical cure
MoA

  • Unknown (resistance mutants identified in vacuolar ATPase sub-unit D indicating possible biological target)
Key features

  • Predicted 280-520mg human dose gives concentrations above Minimal Parasiticidal Concentration for >6 days

  • Low resistance potential from in vitro studies
Challenges

  • Active metabolite; synthesis and cost of goods
Status

  • Approved as preclinical candidate in 2014

  • Licensed to Zydus in September 2016

  • First-in-Human study started in February 2019
Next milestone

  • Confirm human PK
Previously

  • Name AZ13721412; from a discovery partnership between MMV and AstraZeneca, Bangalore
MMV Project Director

  • Dr Andrew Slade